

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM440640

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Sunesis Pharmaceuticals, Inc.		03/31/2016	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Western Alliance Bank		
<b>Street Address:</b>	55 Almaden Boulevard, Suite 100		
<b>Internal Address:</b>	Attn: Loan Operations		
<b>City:</b>	SAN JOSE		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	95113		
<b>Entity Type:</b>	Corporation: ARIZONA		
<b>PROPERTY NUMBERS Total: 11</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	86277611	SUNESIS	
<b>Serial Number:</b>	86277573	SUNESIS	
<b>Serial Number:</b>	86227016		
<b>Serial Number:</b>	85040805	SUNESIS	
<b>Serial Number:</b>	85040780		
<b>Serial Number:</b>	75522022	SUNESIS	
<b>Serial Number:</b>	85909929	VIXVOSAN	
<b>Serial Number:</b>	86707443	QINPREZO	
<b>Serial Number:</b>	85694178	QINPREZO	
<b>Serial Number:</b>	85694169	LADUSOR	
<b>Serial Number:</b>	85909908	ONCYTIQ	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	8586385130		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	619-699-2700		
<b>Email:</b>	susan.reynholds@dlapiper.com		
<b>Correspondent Name:</b>	DLA Piper LLP (US)		
<b>Address Line 1:</b>	401 B Street, Suite 1700		
<b>TRADEMARK</b>			

CH \$290.00 86277611

**Address Line 4:** San Diego, CALIFORNIA 92101

**NAME OF SUBMITTER:** Matt Schwartz

**SIGNATURE:** /s/ Matt Schwartz

**DATE SIGNED:** 08/24/2017

**Total Attachments: 29**

source=IPSA#page1.tif  
source=IPSA#page2.tif  
source=IPSA#page3.tif  
source=IPSA#page4.tif  
source=IPSA#page5.tif  
source=IPSA#page6.tif  
source=IPSA#page7.tif  
source=IPSA#page8.tif  
source=IPSA#page9.tif  
source=IPSA#page10.tif  
source=IPSA#page11.tif  
source=IPSA#page12.tif  
source=IPSA#page13.tif  
source=IPSA#page14.tif  
source=IPSA#page15.tif  
source=IPSA#page16.tif  
source=IPSA#page17.tif  
source=IPSA#page18.tif  
source=IPSA#page19.tif  
source=IPSA#page20.tif  
source=IPSA#page21.tif  
source=IPSA#page22.tif  
source=IPSA#page23.tif  
source=IPSA#page24.tif  
source=IPSA#page25.tif  
source=IPSA#page26.tif  
source=IPSA#page27.tif  
source=IPSA#page28.tif  
source=IPSA#page29.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of March 31, 2016 by and between WESTERN ALLIANCE BANK, an Arizona corporation, as collateral agent for the Lenders (the "Lenders") described in the Loan Agreement (in such capacity, the "Collateral Agent") and SUNESIS PHARMACEUTICALS, INC., a Delaware corporation ("Grantor").

### RECITALS

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the "Loans") in the amounts and manner set forth in that certain Loan and Security Agreement by and between Collateral Agent, the Lenders and Grantor dated as of the date hereof (as the same may be amended, modified or supplemented from time to time, the "Loan Agreement"; capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

### AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest in, to and under its Intellectual Property (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto) included in the Vosaroxin Product Rights and the Product Collateral, and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Lenders, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies.

ANY SUIT, ACTION OR OTHER PROCEEDING ARISING OUT OF OR BASED UPON THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT SHALL BE SUBJECT TO THE PROVISIONS OF SECTION 11 OF THE LOAN AGREEMENT.

*[Balance of Page Intentionally Left Blank]*

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

395 Oyster Point Blvd.  
South San Francisco, California 94080

Attn: Chief Financial Officer

SUNESIS PHARMACEUTICALS, INC.

By:   
Eric Bjerkholt

Title: ~~EVP Corp Dev and Finance, CFO~~

COLLATERAL AGENT:

Address of Collateral Agent:

55 Almaden Boulevard, Suite 100  
San Jose, California 95113  
Attn: Loan Operations

WESTERN ALLIANCE BANK

By: \_\_\_\_\_

Title: \_\_\_\_\_

*[Signature Page to Intellectual Property Security Agreement]*

WEST\268693788  
355157-000250

**TRADEMARK**  
**REEL: 006138 FRAME: 0059**

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

SUNESIS PHARMACEUTICALS, INC.

395 Oyster Point Blvd.  
South San Francisco, California 94080

By: .....

Attn: Chief Financial Officer


Title: .....

COLLATERAL AGENT:

Address of Collateral Agent:

WESTERN ALLIANCE BANK

55 Almaden Boulevard, Suite 100  
San Jose, California 95113  
Attn: Loan Operations

By:  .....

Title: *VP, Director of Portfolio Mgmt*

*{Signature Page to Intellectual Property Security Agreement}*

WEST\266693788  
355157-000250

**TRADEMARK**  
**REEL: 006138 FRAME: 0060**

EXHIBIT A

Copyrights

Description

Registration Number

Registration Date

None

WEST\268693788.3  
355157-000250

**TRADEMARK**  
**REEL: 006138 FRAME: 0061**

EXHIBIT B

Patents

<b>Title</b>	<b>Country</b>	<b>Appln No.</b>	<b>Filed</b>	<b>Patent No.</b>	<b>Granted</b>
Dosing Methods, Combinations and Uses of SNS-595	US	60/553,578	3/15/2004		
SNS-595 and Methods of Using the Same	WIPO	PCT/US05/008346	3/14/2005		
Pharmaceutical Composition Comprising SNS-595 and Uses Thereof	AT	[EP 05731600.2]	3/14/2005	AT E 493982 T1 [EP 1725233 B1]	1/5/2011
SNS-595 and Methods of Using the Same	AU	2005222622	3/14/2005	AU 2005222622 B2	9/29/2011
SNS-595 and Methods of Using the Same	AU	2011201277	3/14/2005	AU 2011201277 B2	3/14/2013
SNS-595 and Methods of Using the Same	AU	2013201203	3/14/2005	AU 2013201203	4/16/2015
SNS-595 and Methods of Using the Same	AU	2015200100	3/14/2005		
Pharmaceutical Composition Comprising SNS-595 and Uses Thereof	BE	[EP 05731600.2]	3/14/2005	[EP 1725233 B1]	1/5/2011
Pharmaceutical Composition Comprising SNS-595 and Uses Thereof	BG	[EP 05731600.2]	3/14/2005	[EP 1725233 B1]	1/5/2011
SNS-595 and Methods of Using the Same	BR	PI0508700-7	3/14/2005		
SNS-595 and Methods of Using the Same	CA	2,559,652	3/14/2005		
Pharmaceutical Composition Comprising SNS-595 and Uses Thereof	CH	[EP 05731600.2]	3/14/2005	[EP 1725233 B1]	1/5/2011
SNS-595 and Methods of Using the Same	CN	200580015456.4	3/14/2005	ZL 200580015456.4	10/22/2014
SNS-595 and Methods of Using the Same	CN	200910221540.1	3/14/2005		
SNS-595 and Methods of Using the Same	CN	201210307920.9	3/14/2005	ZL 201210307920.9	9/30/2015
SNS-595 and Methods of Using the Same	CN	201210307785.8	3/14/2005	ZL 201210307785.8	9/30/2015
SNS-595 and Methods of Using the Same	CN	201410477839.4	3/14/2005		
Pharmaceutical Composition Comprising SNS-595 and Uses Thereof	CY	CY20111100114 [EP 05731600.2]	3/14/2005	CY 1111263 [EP 1725233 B1]	1/5/2011
Pharmaceutical Composition Comprising SNS-595 and Uses Thereof	CZ	[EP 05731600.2]	3/14/2005	[EP 1725233 B1]	1/5/2011

WEST\268693788.3  
355157-000250

Title		Country	Appln No.	Filed	Patent No.	Granted
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	DE	[EP 05731600.2]	3/14/2005	60 2005 025 738.1- 08 [EP 1725233 B1]	1/5/2011
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	DK	[EP 05731600.2]	3/14/2005	[EP 1725233 B1]	1/5/2011
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	EE	[EP 05731600.2]	3/14/2005	E005217 [EP 1725233 B1]	1/5/2011
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	EP	05731600.2	3/14/2005	EP 1725233 B1	1/5/2011
Use of SNS-595 for Leukemia	Treating	EP	10177951.0	3/14/2005	EP 2295056 B1	1/6/2016
Use of SNS-595 for Leukemia	Treating	EP	15202939.3	3/14/2005		
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	ES	[EP 05731600.2]	3/14/2005	ES 2358267 T3 [EP 1725233 B1]	1/5/2011
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	FI	[EP 05731600.2]	3/14/2005	[EP 1725233 B1]	1/5/2011
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	FR	[EP 05731600.2]	3/14/2005	[EP 1725233 B1]	1/5/2011
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	GB	[EP 05731600.2]	3/14/2005	3074565 [EP 1725233 B1]	1/5/2011
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	GR	[EP 05731600.2]	3/14/2005	[EP 1725233 B1]	1/5/2011
SNS-595 and Methods Same	of Using the	HK	07104836.3	3/14/2005	HK 1097196	9/16/2011
SNS-595 and Methods Same	of Using the	HK	11103435.4	3/14/2005		
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	HU	[EP 05731600.2]	3/14/2005	E010709 [EP 1725233 B1]	1/5/2011
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	IE	[EP 05731600.2]	3/14/2005	[EP 1725233 B1]	1/5/2011
SNS-595 and Methods Same	of Using the	IL	177946	3/14/2005		
SNS-595 and Methods Same	of Using the	IN	3809/CHENP/2006	3/14/2005	254943	1/7/2013
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	IS	[EP 05731600.2]	3/14/2005	[EP 1725233 B1]	1/5/2011
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	IT	[EP 05731600.2]	3/14/2005	[EP 1725233 B1]	1/5/2011

WEST\268693788.3  
355157-000250



<b>Title</b>	<b>Country</b>	<b>Appln No.</b>	<b>Filed</b>	<b>Patent No.</b>	<b>Granted</b>	
SNS-595 and Methods of Using the Same	JP	2007-503987	3/14/2005	JP 5317472	7/19/2013	
SNS-595 and Methods of Using the Same	JP	2011-135675	3/14/2005			
SNS-595 and Methods of Using the Same	JP	2014-180862	3/14/2005			
SNS-595 and Methods of Using the Same	KR	10-2006-7021270	3/14/2005	KR 10-1169825	7/24/2012	
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	LT	[EP 05731600.2]	3/14/2005	LT 1725233 [EP 1725233 B1]	1/5/2011
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	LU	[EP 05731600.2]	3/14/2005	[EP 1725233 B1]	1/5/2011
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	MC	[EP 05731600.2]	3/14/2005	[EP 1725233 B1]	1/5/2011
SNS-595 and Methods of Using the Same	MX	PA/a/2006/010382	3/14/2005	MX 295315	1/30/2012	
SNS-595 and Methods of Using the Same	MX	MX/a/2011/011851	3/14/2005			
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	NL	[EP 05731600.2]	3/14/2005	[EP 1725233 B1]	1/5/2011
SNS-595 and Methods of Using the Same	NO	20064647	3/14/2005			
SNS-595 and Methods of Using the Same	NO	20150466	3/14/2005			
SNS-595 and Methods of Using the Same	NZ	549557	3/14/2005			
SNS-595 and Methods of Using the Same	NZ	588060	3/14/2005	NZ 588060	1/9/2012	
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	PL	[EP 05731600.2]	3/14/2005	[EP 1725233 B1]	1/5/2011
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	PT	[EP 05731600.2]	3/14/2005	[EP 1725233 B1]	1/5/2011
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	RO	[EP 05731600.2]	3/14/2005	[EP 1725233 B1]	1/5/2011
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	SE	[EP 05731600.2]	3/14/2005	[EP 1725233 B1]	1/5/2011
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	SL	[EP 05731600.2]	3/14/2005	[EP 1725233 B1]	1/5/2011
Pharmaceutical Comprising SNS-595 Thereof	Composition and Uses	SK	[EP 05731600.2]	3/14/2005	E 9088 T3 [EP 1725233 B1]	1/5/2011

WEST\268693788.3  
355157-000250

Title	Country	Appln No.	Filed	Patent No.	Granted
Pharmaceutical Composition Comprising SNS-595 and Uses Thereof	TR	[EP 05731600.2]	3/14/2005	TR 2011 01843 T4 [EP 1725233 B1]	1/5/2011
Methods of Using SNS-595	US	11/080,283	3/14/2005	US 7989468 B2	8/2/2011
Pharmaceutical Compositions of (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	US	11/478,765	3/14/2005	US 7829577 B2	11/9/2010
SNS-595 and Methods of Using the Same	US	13/159,258	3/14/2005	US 8669270 B2	3/11/2014
SNS-595 and Methods of Using the Same	US	14/171,673	3/14/2005		
SNS-595 and Methods of Using the Same	US	14/996,025	3/14/2005		
SNS-595 and Methods of Using the Same	ZA	2006/07248	3/14/2005	2006/07248	2/25/2009
SNS-595 and Methods of Using the Same	US	60/921,500	9/2/2005		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Cancer	WIPO	PCT/US06/034699	9/5/2006		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Cancer	AU	2006287149	9/5/2006	AU 2006287149	9/5/2013
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Cancer	AU	2013219242	9/5/2006		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Cancer	BR	PI 0615446-8	9/5/2006		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Cancer	CA	2,620,915	9/5/2006	CA 2,620,915 C	3/25/2014

WEST\268693788.3  
355157-000250

Title	Country	Appln No.	Filed	Patent No.	Granted
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Cancer	CA	2,845,095	9/5/2006		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Cancer	CN	200680039484.4	9/5/2006		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Cancer	CN	201510179121.1	9/5/2006		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Cancer	EP	06814231.4	9/5/2006		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Cancer	IN	1608/CHENP/2008	9/5/2006		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Cancer	JP	2008-529378	9/5/2006	JP 5374153	9/27/2013
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Cancer	KR	10-2008-7007886	9/5/2006		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Cancer	KR	10-2014-7010892	9/5/2006		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Cancer	MX	MX/a/2008/002843	9/5/2006		

WEST\268693788.3  
355157-000250

Title	Country	Appln No.	Filed	Patent No.	Granted
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Cancer	MX	MX/a/2014/011960	9/5/2006		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Cancer	RU	2008112679	9/5/2006	2428983	9/20/2011
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Cancer	RU	2011119345	9/5/2006		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Cancer	US	11/991,349	9/5/2006	US 8580814 B2	11/12/2013
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Cancer	US	14/056,877	9/5/2006		
SNS-595 and Methods of Using the Same	WIPO	PCT/US05/008036	3/14/2005		
SNS-595 and Methods of Using the Same	AT	[EP 05732554.0]	3/14/2005	[EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	AU	2005222607	3/14/2005	AU 2005222607 B2	3/10/2011
SNS-595 and Methods of Using the Same	BE	[EP 05732554.0]	3/14/2005	[EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	BG	[EP 05732554.0]	3/14/2005	[EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	CA	2,559,650	3/14/2005	CA 2,559,650	11/19/2013
SNS-595 and Methods of Using the Same	CH	[EP 05732554.0]	3/14/2005	[EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	CY	CY20101100063 [EP 05732554.0]	3/14/2005	CY1109741 [EP 1729770]	12/16/2009
SNS-595 and Methods of Using the Same	CZ	[EP 05732554.0]	3/14/2005	[EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	DE	[EP 05732554.0]	3/14/2005	DE602005018333.7-08 [EP 1729770 B1]	12/16/2009

WEST\268693788.3  
355157-000250

<b>Title</b>	<b>Country</b>	<b>Appln No.</b>	<b>Filed</b>	<b>Patent No.</b>	<b>Granted</b>
SNS-595 and Methods of Using the Same	DK	[EP 05732554.0]	3/14/2005	DK/EP1729770 T3 [EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	EE	[EP 05732554.0]	3/14/2005	E003941 [EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	EP	05732554.0	3/14/2005	EP 1729770 B1	12/16/2009
SNS-595 and Methods of Using the Same	ES	[EP 05732554.0]	3/14/2005	ES 2334802 T3 [EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	FI	[EP 05732554.0]	3/14/2005	[EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	FR	[EP 05732554.0]	3/14/2005	[EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	GB	[EP 05732554.0]	3/14/2005	[EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	GR	[EP 05732554.0]	3/14/2005	3071062 [EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	HU	[EP 05732554.0]	3/14/2005	E007652 [EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	IE	[EP 05732554.0]	3/14/2005	[EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	IS	[EP 05732554.0]	3/14/2005	[EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	IT	[EP 05732554.0]	3/14/2005	[EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	JP	2007-503972	3/14/2005	JP 5096913	9/28/2012
SNS-595 and Methods of Using the Same	JP	2012-036919	3/14/2005		
SNS-595 and Methods of Using the Same	JP	2014-091125	3/14/2005		
SNS-595 and Methods of Using the Same	JP	2015-140309	3/14/2005		
SNS-595 and Methods of Using the Same	LT	[EP 05732554.0]	3/14/2005	1729770 [EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	LU	[EP 05732554.0]	3/14/2005	[EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	MC	[EP 05732554.0]	3/14/2005	[EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	NL	[EP 05732554.0]	3/14/2005	[EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	PL	[EP 05732554.0]	3/14/2005	[EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	PT	[EP 05732554.0]	3/14/2005	[EP 1729770 B1]	12/16/2009

WEST\268693788.3  
355157-000250

<b>Title</b>	<b>Country</b>	<b>Appln No.</b>	<b>Filed</b>	<b>Patent No.</b>	<b>Granted</b>
SNS-595 and Methods of Using the Same	RO	[EP 05732554.0]	3/14/2005	[EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	SE	[EP 05732554.0]	3/14/2005	[EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	SL	[EP 05732554.0]	3/14/2005	P-200530890 [EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	SK	[EP 05732554.0]	3/14/2005	E6925 [EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	TR	[EP 05732554.0]	3/14/2005	TR 2010 01606 T4 [EP 1729770 B1]	12/16/2009
SNS-595 and Methods of Using the Same	US	11/080,102	3/14/2005	US 7968565 B2	6/28/2011
SNS-595 and Methods of Using the Same	US	13/794,583	3/14/2005	US 8822493 B2	9/2/2014
SNS-595 and Methods of Using the Same	US	14/462,439	3/14/2005		
SNS-595 and Methods of Using the Same	US	13/095,111	3/14/2005		
SNS-595 and Methods of Using the Same	US	60/921,501	9/2/2005		
Methods of Using SNS-595 For Treatment of Cancer	US	60/789,093	4/3/2006		
Methods of Using SNS-595 for Treatment of Cancer	US	60/810,285	6/1/2006		
Methods of Using SNS-595 for Treatment of Hematologic Malignancies	US	60/788,927	4/3/2006		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Hematologic Malignancies	US	60/835,239	8/2/2006		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Hematologic Malignancies	US	60/873,760	12/8/2006		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Hematologic Malignancies	WIPO	PCT/US2007/017344	8/2/2007		

WEST\268693788.3  
355157-000250

Title	Country	Appln No.	Filed	Patent No.	Granted
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Hematologic Malignancies	CA	2,659,861	8/2/2007		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Hematologic Malignancies	EP	07811049.1	8/2/2007	EP 2049109 B1	11/18/2015
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Hematologic Malignancies	EP	15189348.4	8/2/2007		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Hematologic Malignancies	JP	2009-522883	8/2/2007		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Hematologic Malignancies	JP	2013-198807	8/2/2007		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Hematologic Malignancies	JP	2015-219880	8/2/2007		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Hematologic Malignancies	MX	MX/a/2009/001130	8/2/2007		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Hematologic Malignancies	MX	MX/a/2015/004306	8/2/2007		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Hematologic Malignancies	US	11/890,196	8/2/2007		

WEST\268693788.3  
355157-000250

Title	Country	Appln No.	Filed	Patent No.	Granted
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for Treatment of Hematologic Malignancies	US	14/461,271	8/2/2007		
Compounds and Compositions for Treatment of Cancer	US	60/812,835	6/12/2006		
Compounds and Compositions for Treatment of Cancer	WIPO	PCT/US2007/013873	6/12/2007		
Compounds and Compositions for Treatment of Cancer	AU	2007258280	6/12/2007	AU 2007258280	8/15/2013
Compounds and Compositions for Treatment of Cancer	BR	PI 0713637-4	6/12/2007		
Compounds and Compositions for Treatment of Cancer	CA	2,654,876	6/12/2007		
Compounds and Compositions for Treatment of Cancer	CN	200780029907.9	6/12/2007	CN 101505753 B	5/21/2014
Compounds and Compositions for Treatment of Cancer	CN	201410211154.5	6/12/2007		
Compounds and Compositions for Treatment of Cancer	EP	07796066.4	6/12/2007		
Compounds and Compositions for Treatment of Cancer	EP	10192053.6	6/12/2007		
Compounds and Compositions for Treatment of Cancer	IL	195883	6/12/2007		
Compounds and Compositions for Treatment of Cancer	IL	243294	6/12/2007		
Compounds and Compositions for Treatment of Cancer	IN	206/CHENP/2009	6/12/2007		
Compounds and Compositions for Treatment of Cancer	JP	2009-515473	6/12/2007		
Compounds and Compositions for Treatment of Cancer	JP	2013-105196	6/12/2007		
Compounds and Compositions for Treatment of Cancer	KR	10-2009-7000459	6/12/2007		
Compounds and Compositions for Treatment of Cancer	MX	MX/a/2008/015775	6/12/2007	300349	6/15/2012
1,8-Naphthyridine Compounds for the Treatment of Cancer	US	12/304,750	6/12/2007	US 8124773 B2	2/28/2012
1,8-Naphthyridine Compounds for the Treatment of Cancer	US	13/360,558	6/12/2007	US 8765954 B2	7/1/2014
1,8-Naphthyridine Compounds for the Treatment of Cancer	US	14/320,414	6/12/2007		

WEST\268693788.3  
355157-000250



Title	Country	Appln No.	Filed	Patent No.	Granted
Pharmaceutical Dosage Forms for (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	US	60/835,148	8/1/2006		
Pharmaceutical Dosage Forms for (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	WIPO	PCT/US2007/017248	8/1/2007		
Pharmaceutical Dosage Forms for (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	US	12/376,118	8/1/2007		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	US	60/981,766	10/22/2007		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	WIPO	PCT/US2008/011960	10/21/2008		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	AU	2008317400	10/21/2008	AU 2008317400 B2	1/15/2015
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	AU	2014277779	10/21/2008		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	CA	2,703,044	10/21/2008		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	CN	200880122398.9	10/21/2008		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	CN	201310524590.3	10/21/2008		

WEST\268693788.3  
355157-000250

**TRADEMARK**  
**REEL: 006138 FRAME: 0072**

Title	Country	Appln No.	Filed	Patent No.	Granted
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	EP	08843165.5	10/21/2008		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	IN	2862/CHENP/2010	10/21/2008		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	JP	2010-531016	10/21/2008		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	JP	2014-212005	10/21/2008		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	MX	MX/a/2010/004350	10/21/2008		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in Combination Therapy	MX	MX/a/2014/001668	10/21/2008		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	US	12/739,139	4/21/2010	US 8518872 B1	8/27/2013
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	US	13/972,800	8/21/2013		
Methods of Using (+)-1,4-Dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	US	14/948,103	8/21/2013		
Methods of Using [SNS-595] for Treatment of Antecedent Hematologic Disorders	US	61/007,229	12/10/2007		
Methods of Using [SNS-595] for Treatment of Antecedent Hematologic Disorders	WIPO	PCT/US2008/013549	12/10/2008		
Methods of Using [SNS-595] for Treatment of Antecedent Hematologic Disorders	AU	2008335772	12/10/2008	AU 2008335772 B2	11/27/2014

WEST\268693788.3  
355157-000250

Title	Country	Appln No.	Filed	Patent No.	Granted
Methods of Using [SNS-595] for Treatment of Antecedent Hematologic Disorders	AU	2015200944	12/10/2008		
Methods of Using [SNS-595] for Treatment of Antecedent Hematologic Disorders	CA	2,708,264	12/10/2008		
[SNS-595] for Use in the Treatment of Antecedent Hematologic Disorders	EP	08858988.2	12/10/2008		
Methods of Using [SNS-595] for Treatment of Antecedent Hematologic Disorders	EP	13166632.3	12/10/2008		
Methods of Using [SNS-595] for Treatment of Antecedent Hematologic Disorders	MX	MX/a/2010/006282	12/10/2008	MX 329422	4/16/2015
Methods of Using [SNS-595] for Treatment of Antecedent Hematologic Disorders	MX	MX/a/2015/004737	12/10/2008		
Methods of Using [SNS-595] for Treatment of Antecedent Hematologic Disorders	US	12/747,167	12/10/2008		
Methods of Using [SNS-595] for Treatment of Antecedent Hematologic Disorders	US	13/477,963	12/10/2008		
Methods of Using [SNS-595] for Treatment of Antecedent Hematologic Disorders	US	14/517,535	12/10/2008		
Compounds and Methods of [sic] for Treatment of Cancer	US	61/069,510	3/13/2008		
Compounds and Methods for Treatment of Cancer	WIPO	PCT/US2009/001588	3/13/2009		
Method of Preparing Voreloxin	US	61/141,856	12/31/2008		
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	WIPO	PCT/US2009/069645	12/29/2009		
Method of Preparing Voreloxin	AR	P090105186	12/31/2009		
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	AU	2009335159	12/29/2009		
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	AU	2015205924	12/29/2009		

WEST\268693788.3  
355157-000250

Title	Country	Appln No.	Filed	Patent No.	Granted
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	BR	PI 0923780-1	12/29/2009		
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	CA	2,748,066	12/29/2009		
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	CN	200980157710.2	12/29/2009	200980157710.2	9/17/2014
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	EP	09796587.5	12/29/2009		
Method of Preparing Voreloxin	GCC	2010/15062	1/2/2010		
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	HK	11113459.4	12/29/2009		
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	ID	W-00201102714	12/29/2009		
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	IL	213708	12/29/2009		
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	IN	5541/CHENP/2011	12/29/2009		
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	JP	2011-544574	12/29/2009		
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	KR	2011-7017736	12/29/2009		

WEST\268693788.3  
355157-000250

Title	Country	Appln No.	Filed	Patent No.	Granted
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	MX	MX/a/2011/006974	12/29/2009	MX 330140	5/19/2015
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	MX	MX/a/2015/006274	12/29/2009		
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	NZ	593763	12/29/2009	NZ 593763	3/4/2014
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	PH	1-2011-501343	12/29/2009		
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	RU	2011132119	12/29/2009	RU 2548031 C2	4/10/2015
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	RU	2015106671	12/29/2009		
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	SG	201104844-4	12/29/2009		
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	SG	10201504789R	12/29/2009		
Method of Preparing Voreloxin	TW	098146462	12/31/2009	1 469980	1/21/2015
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	UA	201109496	12/29/2009	UA 108194	4/10/2015
Method of Preparing Voreloxin	US	12/650,390	12/30/2009	US 8497282 B2	7/30/2013
Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	US	13/940,157	12/30/2009	US 8802719 B2	8/12/2014

WEST\268693788.3  
355157-000250

Title	Country	Appln No.	Filed	Patent No.	Granted
Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	US	14/329,765	12/30/2009		
Method of Preparing Voreloxin	ZA	2011/04610	12/30/2009	2011/04610	3/26/2014
Method of Preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	ZA	2012/07483	12/29/2009		
Methods of Using Voreloxin for Treatment of Cancer Subjects with Reduced BRCA2 Activity	US	61/156,449	2/27/2009		
Methods of Using Voreloxin for Treatment of Cancer Subjects with Reduced BRCA2 Activity	US	61/170,013	4/16/2009		
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	WIPO	PCT/US2010/025737	3/1/2010		
Methods of Using SNS-595 [Voreloxin?] for Treatment of Cancer Subjects with Reduced BRCA2 Activity	WIPO	PCT/US2010/025367	2/25/2010		
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	AU	2010217796	3/1/2010	2010217796	8/13/2015
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	AU	2015207901	3/1/2010		
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	BR	PI 1013172-8	3/1/2010		
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	CA	2,753,261	3/1/2010		
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	CN	201080017203.1	3/1/2010		
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	CN	201410799921.9	3/1/2010		
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	EP	10707173.0	3/1/2010		

WEST\268693788.3  
355157-000250

<b>Title</b>	<b>Country</b>	<b>Appln No.</b>	<b>Filed</b>	<b>Patent No.</b>	<b>Granted</b>
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	HK	12100242.2	3/1/2010		
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	ID	W-00201103415	3/1/2010		
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	IL	214784	3/1/2010		
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	IN	6840/CHENP/2011	3/1/2010		
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	JP	2011-552217	3/1/2010		
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	JP	2015-060900	3/1/2010		
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	KR	2011-7022340	3/1/2010		
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	MX	MX/a/2011/008994	3/1/2010		
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	NZ	594829	3/1/2010	NZ 594829	1/7/2014
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	PH	1-2011-501721	3/1/2010		
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	RU	2011139323	3/1/2010		
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	SG	201106151-2	3/1/2010		
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	SG	10201400258S	3/1/2010		
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	UA	201111392	3/1/2010	UA 103917 C2	12/10/2013
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	US	13/203,718	3/1/2010		

WEST\268693788.3  
355157-000250

<b>Title</b>	<b>Country</b>	<b>Appln No.</b>	<b>Filed</b>	<b>Patent No.</b>	<b>Granted</b>
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	US	14/476,606	3/1/2010		
Methods of Using SNS-595 for Treatment of Cancer Subjects with Reduced BRCA2 Activity	ZA	2011/06199	3/1/2010	ZA 2011/06199	10/31/2012
Stable SNS-595 Compositions and Methods of Preparation	US	61/240,161	9/4/2009		
Stable SNS-595 Compositions and Methods of Preparation	WIPO	PCT/US2010/047776	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	AT	[EP 10759761.9]	9/3/2010	[EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	AU	2010289337	9/3/2010	AU 2010289337 B2	2/12/2015
Stable SNS-595 Compositions and Methods of Preparation	AU	2013202641	9/3/2010	AU 2013202641 B2	11/5/2015
Stable SNS-595 Compositions and Methods of Preparation	AU	2015246121	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	BE	[EP 10759761.9]	9/3/2010	[EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	BR	PI 11 2012 004916 0	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	CA	2,772,291	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	CH	[EP 10759761.9]	9/3/2010	[EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	CL	565-2012	9/3/2010	565-2012	1/17/2016
Stable SNS-595 Compositions and Methods of Preparation	CL	446-2014	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	CN	201080050160.7	9/3/2010	CN 102596946 B	7/22/2015
Stable SNS-595 Compositions and Methods of Preparation	CN	201410318200.1	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	CO	12-038188	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	CZ	[EP 10759761.9]	9/3/2010	[EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	DE	[EP 10759761.9]	9/3/2010	602010014465.8 [EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	DK	[EP 10759761.9]	9/3/2010	[EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	EA	201270377	9/3/2010		

WEST\268693788.3  
355157-000250



<b>Title</b>	<b>Country</b>	<b>Appln No.</b>	<b>Filed</b>	<b>Patent No.</b>	<b>Granted</b>
Stable SNS-595 Compositions and Methods of Preparation	EA	201400683	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	EE	[EP 10759761.9]	9/3/2010	[EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	EP	10759761.9	9/3/2010	EP 2473507 B1	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	EP	13184180.1-1452	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	ES	[EP 10759761.9]	9/3/2010	[EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	FI	[EP 10759761.9]	9/3/2010	[EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	FR	[EP 10759761.9]	9/3/2010	[EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	GB	[EP 10759761.9]	[EP 9/3/2010	[EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	HK	12112980.3	9/3/2010	HK 1172032	11/7/2014
Stable SNS-595 Compositions and Methods of Preparation	HK	14104775.7	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	HR	[EP 10759761.9]	9/3/2010	P20140372T [EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	HU	[EP 10759761.9]	9/3/2010	[EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	ID	W-00201200809	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	IE	[EP 10759761.9]	9/3/2010	[EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	IL	218404	9/3/2010	218404	10/31/2015
Stable SNS-595 Compositions and Methods of Preparation	IL	237724	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	IN	1992/CHENP/2012	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	IT	[EP 10759761.9]	9/3/2010	[EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	JP	2012-528076	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	KR	2012-7008282	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	LT	[EP 10759761.9]	9/3/2010	[EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	LV	[EP 10759761.9]	9/3/2010	[EP 2473507 B1]	3/19/2014

WEST\268693788.3  
355157-000250

<b>Title</b>	<b>Country</b>	<b>Appln No.</b>	<b>Filed</b>	<b>Patent No.</b>	<b>Granted</b>
Stable SNS-595 Compositions and Methods of Preparation	MX	MX/a/2012/002573	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	MX	MX/a/2013/012672	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	NL	[EP 10759761.9]	9/3/2010	[EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	NO	[EP 10759761.9]	9/3/2010	[EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	NZ	598467	9/3/2010	NZ 598467	8/1/2014
Stable SNS-595 Compositions and Methods of Preparation	NZ	623780	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	PH	1-2012-500433	9/3/2010	1-2012-500433	5/14/2015
Stable SNS-595 Compositions and Methods of Preparation	PH	1-2014-500714	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	PL	[EP 10759761.9]	9/3/2010	[EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	PT	[EP 10759761.9]	9/3/2010	[EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	RO	[EP 10759761.9]	9/3/2010	[EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	SE	[EP 10759761.9]	9/3/2010	[EP 2473507 B1]	3/19/2014
Stable SNS-595 Compositions and Methods of Preparation	SG	201201486-6	9/3/2010	SG 178956	10/31/2014
Stable SNS-595 Compositions and Methods of Preparation	SG	201401316-3	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	TW	099129946	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	TW	103137080	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	UA	201204145	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	UA	201508266	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	US	12/875,927	9/3/2010	US 8586601 B2	11/19/2013
Stable SNS-595 Compositions and Methods of Preparation	US	12/982,785	9/3/2010	US 8138202 B2	3/20/2012
Stable SNS-595 Compositions and Methods of Preparation	US	14/055,590	9/3/2010		
Stable SNS-595 Compositions and Methods of Preparation	US	15/064,498	9/3/2010		

WEST\268693788.3  
355157-000250

Title	Country	Appln No.	Filed	Patent No.	Granted
Stable SNS-595 Compositions and Methods of Preparation	ZA	2012/01469	9/3/2010	2012/01469	5/29/2013
Stable SNS-595 Compositions and Methods of Preparation	ZA	2013/01487	9/3/2010		
Stable SNS-595 Products	US	61/240,113			
Compounds and Methods for Treatment of Cancer	US	61/255,039	10/26/2009		
Compounds and Methods for Treatment of Cancer	WIPO	PCT/US2010/054086	10/26/2010		
Compounds and Methods for Treatment of Cancer	TW	099136576	10/26/2010		
Compounds and Methods for Treatment of Cancer	US	12/912,617	10/26/2010	US 8470817 B2	6/25/2013
Lyophilized compositions of (+)-1,4-dihydro-7-[(3 <i>S</i> ,4 <i>S</i> )-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid	US	61/288,213	12/18/2009		
Novel Compound, Process for Producing the Same, and Antitumor Agent	WIPO	PCT/JP95/01110	6/6/1995		
Novel Compound, Process for Producing the Same, and Antitumor Agent	AR	950100147	11/13/1995	AR003914 B1	7/6/2001
Novel Compound, Process for Producing the Same, and Antitumor Agent	AT	[EP 95 920265.6]	6/6/1995	[EP 0787726 B1]	11/28/2001
Novel Compounds, Processes for the Preparation Thereof, and Anti-Tumour Agents	AU	25767/95	12/6/1996	AU 679859 B2	10/30/1997
Novel Compound, Process for Producing the Same, and Antitumor Agent	BE	[EP 95 920265.6]	6/6/1995	[EP 0787726 B1]	11/28/2001
Novel Compound, Process for Producing the Same, and Antitumor Agent	BR	PI 9508037-6	6/6/1995	PI 9508037-6	4/15/2003
Pyridone-Carboxylic Acid Derivatives, Processes for the Preparation Thereof and Anti-Tumour Agents Containing the Pyridone-Carboxylic Acid Derivatives	CA	2192824	6/6/1995	CA 2192824 C	11/7/2006
Novel Compound, Process for Producing the Same, and Antitumor Agent	CH	[EP 95 920265.6]	6/6/1995	[EP 0787726 B1]	11/28/2001

WEST\268693788.3  
355157-000250

<b>Title</b>	<b>Country</b>	<b>Appln No.</b>	<b>Filed</b>	<b>Patent No.</b>	<b>Granted</b>
Novel Compound, Process for Producing the Same, and Antitumor Agent	CN	95194461.4	6/6/1995	CN 1053668 C	3/17/2000
Novel Compound, Process for Producing the Same, and Antitumor Agent	CZ	PV 3643/96	6/6/1995	292631	9/5/2003
Novel Compound, Process for Producing the Same, and Antitumor Agent	DE	[EP 95 920265.6]	6/6/1995	[EP 0787726 B1]	11/28/2001
Novel Compound, Process for Producing the Same, and Antitumor Agent	DK	[EP 95 920265.6]	6/6/1995	[EP 0787726 B1]	11/28/2001
Novel Compound, Process for Producing the Same, and Antitumor Agent	EP	95920265.6	6/6/1995	EP 0787726 B1	11/28/2001
Novel Compound, Process for Producing the Same, and Antitumor Agent	ES	[EP 95 920265.6]	6/6/1995	[EP 0787726 B1]	11/28/2001
Novel Compound, Process for Producing the Same, and Antitumor Agent	FI	96 5020	6/6/1995	112485	12/15/2003
Novel Compound, Process for Producing the Same, and Antitumor Agent	FR	[EP 95 920265.6]	6/6/1995	[EP 0787726 B1]	11/28/2001
Novel Compound, Process for Producing the Same, and Antitumor Agent	GB	[EP 95 920265.6]	6/6/1995	[EP 0787726 B1]	11/28/2001
Novel Compound, Process for Producing the Same, and Antitumor Agent	GR	[EP 95 920265.6]	6/6/1995	[EP 0787726 B1]	11/28/2001
Novel Compound, Process for Producing the Same, and Antitumor Agent	HK	97 101948.5	6/6/1995	1000495B	7/19/2002
Novel Compound, Process for Producing the Same, and Antitumor Agent	HU	P 96 03455	6/6/1995	220072	10/29/2001
Novel Compound, Process for Producing the Same, and Antitumor Agent	IE	[EP 95 920265.6]	6/6/1995	[EP 0787726 B1]	11/28/2001
Novel Compound, Process for Producing the Same, and Antitumor Agent	IL	115726	6/6/1995	115726	3/1/2000
Novel Compound, Process for Producing the Same, and Antitumor Agent	IT	[EP 95 920265.6]	6/6/1995	[EP 0787726 B1]	11/28/2001

WEST\268693788.3  
355157-000250

<b>Title</b>	<b>Country</b>	<b>Appln No.</b>	<b>Filed</b>	<b>Patent No.</b>	<b>Granted</b>
Novel Compound, Process for Producing the Same, and Antitumor Agent	JP	8-501923	6/6/1995	3391796	1/24/2003
Novel Compound, Process for Producing the Same, and Antitumor Agent	JP	8-351948	6/6/1995	4323574	6/12/2009
Novel Compound, Process for Producing the Same, and Antitumor Agent	JP	10-173986	6/6/1995	4294121	4/17/2009
Novel Compound, Process for Producing the Same, and Antitumor Agent	KR	707029/1996	6/6/1995	350921	8/20/2002
Novel Compound, Process for Producing the Same, and Antitumor Agent	LT	[EP 95 920265.6]	6/6/1995	[EP 0787726 B1]	11/28/2001
Novel Compound, Process for Producing the Same, and Antitumor Agent	LU	[EP 95 920265.6]	6/6/1995	[EP 0787726 B1]	11/28/2001
Novel Compound, Process for Producing the Same, and Antitumor Agent	LV	[EP 95 920265.6]	6/6/1995	[EP 0787726 B1]	11/28/2001
Novel Compound, Process for Producing the Same, and Antitumor Agent	MC	[EP 95 920265.6]	6/6/1995	[EP 0787726 B1]	11/28/2001
Novel Compound, Process for Producing the Same, and Antitumor Agent	MX	96 6331	6/6/1995	217374	11/6/2003
Novel Compound, Process for Producing the Same, and Antitumor Agent	NL	[EP 95 920265.6]	6/6/1995	[EP 0787726 B1]	11/28/2001
Novel Compound, Process for Producing the Same, and Antitumor Agent	NO	96.5305	6/6/1995	307255	3/6/2000
Novel Compound, Process for Producing the Same, and Antitumor Agent	NZ	287139	6/6/1995	287139	11/19/1997
Novel Compound, Process for Producing the Same, and Antitumor Agent	PH	51621	11/2/1995	1-1995-51621	8/5/2003
Novel Compound, Process for Producing the Same, and Antitumor Agent	PK	564/95	10/23/1995	134868	10/23/1997
Novel Compound, Process for Producing the Same, and Antitumor Agent	PL	P 317726	6/6/1995	181867	3/1/2001

WEST\268693788.3  
355157-000250

<b>Title</b>	<b>Country</b>	<b>Appln No.</b>	<b>Filed</b>	<b>Patent No.</b>	<b>Granted</b>
Novel Compound, Process for Producing the Same, and Antitumor Agent	PT	[EP 95 920265.6]	6/6/1995	[EP 0787726 B1]	11/28/2001
Novel Compound, Process for Producing the Same, and Antitumor Agent	RO	96-02349	6/6/1995	117793	6/19/2002
Novel Compound, Process for Producing the Same, and Antitumor Agent	RU	97 100718	6/6/1995	2151770	6/27/2000
Novel Compound, Process for Producing the Same, and Antitumor Agent	SE	[EP 95 920265.6]	6/6/1995	[EP 0787726 B1]	11/28/2001
Novel Compound, Process for Producing the Same, and Antitumor Agent	SG	96 12283-3	6/6/1995	37810	12/19/1997
Novel Compound, Process for Producing the Same, and Antitumor Agent	SL	[EP 95 920265.6]	6/6/1995	[EP 0787726 B1]	11/28/2001
Novel Compound, Process for Producing the Same, and Antitumor Agent	SK	PV 1574/96	6/6/1995	281341	11/8/2000
Novel Compound, Process for Producing the Same, and Antitumor Agent	TW	84 106000	6/6/1995	90869	3/18/1998
Compounds, Processes for the Preparation Thereof and Anti-Tumor Agents	US	08/765,232	6/6/1995	US 5817669	10/6/1998
Novel Compound, Process for Producing the Same, and Antitumor Agent	ZA	95/9030	10/25/1995	95/9030	8/28/1996

WEST\268693788.3  
355157-000250

EXHIBIT C

Trademarks

<u>Description</u>	<u>Serial/Registration No.</u>	<u>File Date</u>
SUNESIS	86277611	5/9/14
SUNESIS	86277573	5/9/14
Design	86227016	8/2/12
SUNESIS	85040805	5/17/10
Design	85040780	5/17/10
SUNESIS	75522022	7/20/96
VIXVOSAN	85909929	4/19/13
QINPREZO	86707443	7/28/15
QINPREZO	85694178	8/2/12
LADUSOR	85694169	8/2/12
ONCYTIQ	85909908	4/19/13